Site-Specific Capsid Modification Enables FRα-Directed Retargeting of AAV for Precision Gene Delivery
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Yuanjie Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. Hauptthemen laut MEDLINE: Dependovirus, Capsid, Gene Transfer Techniques, Folate Receptor 1. Die Arbeit nennt 62 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Shenzhen Bay Laboratory, National Natural Science Foundation of China.
Abstract (Originalsprache)
The clinical translation of adeno-associated virus (AAV)-based gene therapies is often hindered by nonselective tissue transduction, off-target uptake by nontarget cells, and unintended toxicity to healthy tissues. To overcome these challenges, we previously developed a site-specific AAV capsid engineering strategy involving the incorporation of an azide-bearing unnatural amino acid (NAEK) into defined capsid positions, enabling precise, bioorthogonal conjugation of targeting ligands. In this study, we applied this approach to generate a series of folate receptor α (FRα)-targeted AAV2 vectors through covalent tethering of folic acid (FA) at specific capsid residues. FA conjugation at residues S264 + 1 and Q325 significantly enhanced FRα-mediated transduction, yielding a 3-5-fold increase in gene transfer efficiency in FRα-positive tumor cells. Structure-activity relationship analysis revealed that transduction selectivity is governed not only by ligand-receptor binding affinity but also by the spatial location of the conjugation site, which influences competition with the native AAV receptor (AAVR). Importantly, this modular conjugation platform allows for facile replacement of ligands, enabling the rational design of receptor-directed AAV vectors for targeted and cell-specific gene therapy. These findings provide mechanistic insights into capsid-receptor interactions and establish a flexible strategy for precision engineering of AAV-based delivery systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
- Shenzhen Bay Laboratory, Gaoke International Innovation Center, Shenzhen, Guangdong 518107, China.
- Peking University Ningbo Institute of Marine Medicines, Ningbo, Zhejiang 315832, China.
- Peking University - Yunnan Baiyao International Medical Research Center, Beijing 100191, China.
ORCID-Profile: Sulong Xiao, Chuanling Zhang
Förderung
- National Key Research and Development Program of China
- Shenzhen Bay Laboratory
- National Natural Science Foundation of China
- Ningbo Key Science and Technology Development Program
Zitieren
APA
Zhang, Y., Shi, Y., Zhou, X., Han, X., Wang, F., Zhang, J., Luo, J., Wang, X., Wang, Y., Ji, D., Xiao, S., Wang, Q., Zhang, L., Zhang, C., & Zhou, D. (2026). Site-Specific Capsid Modification Enables FRα-Directed Retargeting of AAV for Precision Gene Delivery. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01166
Vancouver
Zhang Y, Shi Y, Zhou X, Han X, Wang F, Zhang J, et al. Site-Specific Capsid Modification Enables FRα-Directed Retargeting of AAV for Precision Gene Delivery. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01166
BibTeX
@article{Zhang2026,
author = {Zhang, Yuanjie and Shi, Yingying and Zhou, Xueying and Han, Xu and Wang, Fudi and Zhang, Jiawen and Luo, Jinhuan and Wang, Xiaoyang and Wang, Yiming and Ji, Dezhong and Xiao, Sulong and Wang, Qi and Zhang, Lihe and Zhang, Chuanling and Zhou, Demin},
title = {Site-Specific Capsid Modification Enables FRα-Directed Retargeting of AAV for Precision Gene Delivery},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01166}
}
EUVIMED